(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN - 2NASA shares first photos of Earth taken by Artemis II
- 3Abbott issues US device correction for some glucose monitors over faulty readings risk
- 4Brazil passes anti-gang law allowing seized crypto to fund security forces
- 5‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Lightning on Jupiter could be up to 1 million times stronger than on Earth
- Nations for Youngsters to Visit
- Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- The Solution to Individual budget: Dominating Cash The board
- Porsche May Kill the Electric Boxster Before It Ever Arrives
- China and Pakistan issue five-point peace plan for Middle East
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- Vote in favor of Your Number one BWM Vehicles
